Discontinued — last reported Q1 '18
Cboe Global Markets Allowance for Doubtful Accounts Receivable (Current) decreased by 2.9% to $6.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.0%, from $7.50M to $6.60M. Over 2 years (FY 2023 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows an upward trend with a 22.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $4.50M | $7.00M | $6.60M | $7.50M | $8.70M | $6.60M | $6.80M | $6.60M |
| QoQ Change | — | +55.6% | -5.7% | +13.6% | +16.0% | -24.1% | +3.0% | -2.9% |
| YoY Change | — | — | +46.7% | — | — | -5.7% | +3.0% | -12.0% |